Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
The group released several reports on these effects as a cover story, claiming that their ionospheric studies had been interfering with the other experiments at the RRS at Slough, and expressing their gratitude that the Air Ministry had granted them access to unused land at Orfordness to continue their efforts. Bowen continued increasing the voltage in the transmitter, starting with the 5000 volt maximum suggested by the Navy, but increasing in steps over several months to 12,000 V, which produced pulses of 200 kW. Arcing between the valves required the transmitter to be rebuilt with more room between them, while arcing on the antenna was solved by hanging copper balls from the dipole to reduce corona discharge. By June the system was working well, although Bainbridge-Bell proved to be so skeptical of success that Watt eventually returned him to the RRS and replaced him with Nick Carter. The Tizard Committee visited the site on 15 June to examine the team's progress. Watt secretly arranged for a Vickers Valentia to fly nearby, and years later insisted that he saw the echoes on the display, but no one else recalls seeing these. Watt decided not to return to the RRS with the rest of the Tizard group and stayed with the team for another day. With no changes made to the equipment, on 17 June the system was turned on and immediately provided returns from an object at 17 mi (27 km). After tracking it for some time, they watched it fly off to the south and disappear.
By 1942, Germany and its allies controlled most of continental Europe and North Africa, but following the Soviet victory at the Battle of Stalingrad, the Allied reconquest of North Africa and invasion of Italy in 1943, German forces suffered repeated military defeats. In 1944, the Soviets pushed into Eastern Europe; the Western allies landed in France and entered Germany despite a final German counteroffensive. Following Hitler's suicide during the Battle of Berlin, Germany signed the surrender document on 8 May 1945, ending World War II in Europe and Nazi Germany. After the war, surviving Nazi officials were tried for war crimes at the Nuremberg trials. Discrimination was institutionalised through legislation and perpetrated at an industrial scale with concentration and death camps across Europe. The crimes against humanity culminated in but were not limited to what later became known as the Holocaust, the systematic murdering of around 6 million Jews. Several other minority groups were targeted: at least 130,000 Romani, 275,000 disabled, thousands of Jehovah's Witnesses, thousands of homosexuals, and hundreds of thousands of political and religious opponents. Nazi policies in German-occupied countries resulted in the deaths of an estimated 2.7 million Poles, 1.3 million Ukrainians, 1 million Belarusians and 3.5 million Soviet prisoners of war. German military casualties have been estimated at 5.3 million, and around 900,000 German civilians died.
=== Direct immunofluorescence testing === The presence of Immunoglobulin G, A, or M in the epidermis is normal. Detection in other locations such as intercellular and areas below the epidermis (subepidermal), as well as along the dermoepidermal junction (area that joins the epidermis and dermis), suggests paraneoplastic pemphigus.
The safe storage of food for home use should strictly adhere to guidelines set out by reliable sources, such as the United States Department of Agriculture or the European Food Safety Authority. Scientists have thoroughly researched these guidelines to determine the most effective methods for reducing the real threat of food poisoning caused by unsafe food storage. It is also important to maintain proper kitchen hygiene to reduce the risk of bacterial or viral growth and food poisoning. The common food poisoning illnesses include Listeriosis, Mycotoxicosis, Salmonellosis, E. coli, Staphylococcal food poisoning and Botulism. Many other organisms can also cause food poisoning. There are also safety guidelines for the correct methods of home canning. For example, there are specific boiling times that apply depending upon whether pressure canning or waterbath canning is being used in the process. These safety guidelines are intended to reduce the growth of mold and bacteria and the threat of potentially fatal food poisoning.
== Mechanical comminution == Mechanical comminution is the dominant family of techniques for industrial micronization. The process typically begins with coarse size reduction — crushing by hammer or impact mills and cutting by blade mills — which produces feed material in the millimetre-to-coarse-micrometre range from bulk solids. Conventional tumbling ball mills, in which a rotating drum loaded with steel or ceramic grinding media reduces the feed by impact and abrasion, are widely used for grinding in the 50–500 μm range but do not typically achieve micrometre-scale particle sizes on their own. True micronization to the 1–10 μm range is achieved by higher-energy mechanical techniques, principally jet milling for dry powders and wet bead milling or high-pressure homogenization for aqueous suspensions, which are described in the following sections. Industrial pharmaceutical micronization is dominated by mechanical comminution methods, particularly air-jet milling (also called fluid energy milling) and cryogenic milling. These mechanical methods scale from gram-level development batches to multi-metric-ton commercial campaigns and operate under current good manufacturing practice (cGMP) regulations such as 21 CFR Part 211 and ICH Q7. The choice of micronization technology depends on the active pharmaceutical ingredient's physical properties. Air-jet milling produces narrow, log-normal particle-size distributions typically with D50 below 5 µm and span ≤ 2, and is the standard approach for dry powder inhalation products and poorly soluble oral solids.
Sources: en.wikipedia.org
=== Ancient === 350 BCE — The Greek philosopher Aristotle, arguably the first philosopher to make a serious attempt to scientifically explain aging, proposes his thesis on aging. He suggests that aging is a process by which human and animal bodies, which are naturally hot and wet, gradually become dry and cold, and theorizes that more moisture delays aging. 259–210 BCE — years of life of the Chinese emperor Qin Shi Huang, who united China under his rule. All his life he persistently searched for an elixir of youth and died trying, presumably taking "pills of immortality", containing mercury. 156–87 BCE — years of life of the Chinese emperor Wu of Han, who persistently tried to find a way to achieve immortality, mainly by means of magic. He used services of various magicians. But Wu of Han was not a naive person – he thoroughly rechecked their abilities and if he identified the person as a quack, he executed him. 63 BC–14 CE — years of life of Caesar Augustus, the first Roman emperor, who is considered one of the most effective leaders of the Ancient Rome. For him an eternal youth was an obsession. In particular, contrary to the Roman tradition to create statues as realistic as possible, he always ordered to portray himself young. There are many of his "youthful" statues but researchers still do not know how he looked in old age. 3rd–17th century — the period of alchemy. There are several directions in alchemy, and it was distributed over a huge territory.
==== Positive criminology and positive victimology ==== Positive criminology and positive victimology are conceptual approaches, developed by the Israeli criminologist Natti Ronel and his research team, that follow principles of positive psychology and apply them into the fields of criminology and victimology, respectively. Positive criminology and victimology both place an emphasis on social inclusion and on unifying and integrating forces at individual, group, social and spiritual levels that are associated with the limiting of crime and recovery from victimization. In traditional approaches, the study of crime, violence and related behaviors emphasizes the negative aspects in people's lives that are associated with deviance, criminality and victimization. A common understanding is that human relationships are affected more by destructive encounters than by constructive or positive ones. Positive criminology and victimology argue that a different approach is viable, based on three dimensions – social integration, emotional healing and spirituality – that constitute positive direction indicators.
The Chinese Physical Society (CPS) is a professional society of physicists established in 1932. It is part of the China Association for Science and Technology. Current membership is at around 40,000. CPS has been a member of the International Union of Pure and Applied Physics (IUPAP) since 1984 and of the Association of Asia Pacific Physical Societies (AAPPS) since 1990.
Lücking and colleagues (2021) emphasize distinguishing real species from minor variants with differing allele frequencies or subtle sequence divergence. These issues reflect the balance between scientific progress and maintaining a practical, stable nomenclature for ecological and conservation work. The LPR framework is one attempt to impose a higher bar: requiring evidence of reproductive isolation or ecological differentiation, not just genetic distinctness, to call something a new species. Additionally, nomenclatural stability is an ongoing issue. When molecular studies reorder relationships, it often necessitates changes in genus or family assignments. The 2016 global lichen classification (and its 2017 update) made hundreds of such changes to align names with phylogeny. They noted that fully half of all lichen genera had to be moved to a different family or order compared to the previous decade's understanding. These scientifically justified changes can be disruptive for end-users like ecologists or land managers who suddenly have to learn new names for familiar organisms. The challenge for systematists is to communicate these changes clearly and perhaps even temper the pace of renaming by holding off until results are strongly corroborated. Some stability measures (like proposing nomenclatural conservation of widely used names even if they are technically nested in another group) can mitigate the impact on the broader community.
The cellular response in signal transduction cascades involves alteration of the expression of effector genes or activation/inhibition of targeted proteins. Regulation of protein activity mainly involves phosphorylation/dephosphorylation events, leading to its activation or inhibition. It is the case for the vast majority of responses as a consequence of the binding of the primary messengers to membrane receptors. This response is quick, as it involves regulation of molecules that are already present in the cell. On the other hand, the induction or repression of the expression of genes requires the binding of transcriptional factors to the regulatory sequences of these genes. The transcriptional factors are activated by the primary messengers, in most cases, due to their function as nuclear receptors for these messengers. The secondary messengers like DAG or Ca2+ could also induce or repress gene expression, via transcriptional factors. This response is slower than the first because it involves more steps, like transcription of genes and then the effect of newly formed proteins in a specific target. The target could be a protein or another gene.
Sources: en.wikipedia.org
The calculations given above produce dates in radiocarbon years: i.e. dates that represent the age the sample would be if the 14C/12C ratio had been constant historically. Although Libby had pointed out as early as 1955 the possibility that this assumption was incorrect, it was not until discrepancies began to accumulate between measured ages and known historical dates for artefacts that it became clear that a correction would need to be applied to radiocarbon ages to obtain calendar dates. To produce a curve that can be used to relate calendar years to radiocarbon years, a sequence of securely dated samples is needed which can be tested to determine their radiocarbon age. The study of tree rings led to the first such sequence: individual pieces of wood show characteristic sequences of rings that vary in thickness because of environmental factors such as the amount of rainfall in a given year. These factors affect all trees in an area, so examining tree-ring sequences from old wood allows the identification of overlapping sequences. In this way, an uninterrupted sequence of tree rings can be extended far into the past. The first such published sequence, based on bristlecone pine tree rings, was created by Wesley Ferguson. Hans Suess used this data to publish the first calibration curve for radiocarbon dating in 1967. The curve showed two types of variation from the straight line: a long term fluctuation with a period of about 9,000 years, and a shorter-term variation, often referred to as "wiggles", with a period of decades.
As of 2025, many companies are researching and manufacturing new insulin analogues. These insulins are usually designed to be either ultra-short-acting or ultra-long-acting. Insulin degludec, an ultra-long-acting insulin analog, was developed by Novo Nordisk and approved by the FDA in 2015. Insulin degludec has an extended duration of action, lasting up to 42 hours, offering greater flexibility in dosing schedules. In March 2024, insulin icodec was approved for medical use in Canada. The same month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion, recommending the granting of marketing authorization for Awiqli, under which insulin icodec is marketed. Following the CHMP's recommendation, insulin icodec was approved for medical use in the European Union in May 2024. Insulin icodec has a plasma half-life more than eight days (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.
== Potential applications == The primary proposed benefit of creating mirror-image organisms is as a means to mass-produce mirror-image forms of molecules that are produced by normal life. Mirror-image molecules have been studied for several decades and may offer a range of potential applications. There is broad agreement among scientists that it is important to distinguish between mirror-image molecules and whole mirror-image organisms. Some scientists argue that chemical synthesis methods are sufficient for creating mirror-image molecules without posing the potentially catastrophic risks of mirror-image organisms. Potential applications of mirror-image molecules include:
Severe cardiovascular disease such as unstable angina or poorly controlled hypertension Increased intracranial or intraocular pressure (however these remain controversial, with recent studies suggesting otherwise) Poorly controlled psychosis Severe liver disease such as cirrhosis Pregnancy Active substance use disorder (for serial ketamine injections) Age less than 3 months
== Measurement and values == Measurement is done from a sample of venous blood using immunological measuring mechanisms like ELISA, RIA, etc. Often these are done by automated machines to minimize human error.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.